Insider Selling: Maze Therapeutics (NASDAQ:MAZE) CEO Sells 11,411 Shares of Stock

Maze Therapeutics, Inc. (NASDAQ:MAZE) CEO Jason Coloma sold 11,411 shares of the business’s stock in a transaction on Thursday, September 3rd. The shares were sold at an average price of $26.01, for a total transaction of $296,800.11. Following the sale, the chief executive officer directly owned 27,362 shares of the company’s stock, valued at $711,685.62. This represents a 29.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Maze Therapeutics Trading Up 1.3%

MAZE stock traded up $0.34 during trading on Friday, hitting $26.21. The company had a trading volume of 273,266 shares, compared to its average volume of 637,671. Maze Therapeutics, Inc. has a 52-week low of $14.27 and a 52-week high of $53.65. The company has a 50 day simple moving average of $28.74 and a 200-day simple moving average of $31.20. The firm has a market capitalization of $1.46 billion, a P/E ratio of -10.40 and a beta of 2.17. The company has a quick ratio of 18.31, a current ratio of 18.31 and a debt-to-equity ratio of 0.09.

Maze Therapeutics (NASDAQ:MAZE) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.76) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.76). As a group, research analysts forecast that Maze Therapeutics, Inc. will post -2.72 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms have commented on MAZE. TD Cowen upgraded Maze Therapeutics to a “strong-buy” rating in a report on Monday, August 24th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a report on Wednesday, June 24th. BTIG Research reissued a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Finally, Wall Street Zen lowered Maze Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Three investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $66.00.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada increased its holdings in shares of Maze Therapeutics by 128.3% in the 4th quarter. Royal Bank of Canada now owns 646 shares of the company’s stock valued at $27,000 after acquiring an additional 363 shares during the period. Ameritas Investment Partners Inc. boosted its position in Maze Therapeutics by 82.6% during the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after purchasing an additional 738 shares in the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Maze Therapeutics during the fourth quarter valued at about $43,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in Maze Therapeutics in the second quarter valued at about $48,000. Finally, Russell Investments Group Ltd. raised its holdings in Maze Therapeutics by 947.8% in the third quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock worth $49,000 after purchasing an additional 1,725 shares in the last quarter.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.